The use of bemiparin to prevent deep vein thrombosis in plastic and reconstructive surgery patients

Submission date	Recruitment status	Prospectiv
16/08/2019	No longer recruiting	[_] Protocol
Registration date	Overall study status	[] Statistical
27/08/2019	Completed	[X] Results
Last Edited 18/02/2020	Condition category Circulatory System	[_] Individual

] Prospectively registered

Statistical analysis plan

] Individual participant data

Plain English summary of protocol

Background and study aims

Deep vein thrombosis (DVT) is a blood clot that develops within a deep vein in the body, usually in the leg.It can cause pain and swelling in the leg and may lead to complications such as pulmonary embolism. This is a serious condition that occurs when a piece of blood clot breaks off into the bloodstream and blocks one of the blood vessels in the lungs.

DVT is a common complication during postoperative convalescence. Both the complexity and frequency of plastic and reconstructive surgery (PRSx) procedures have significantly increased in Mexico over the last 25 years. It has become necessary to find more effective measures to prevent DVT. The aim of this study was to evaluate the efficacy and safety of bemiparin compared to enoxaparin for the prevention of DVT

Who can participate? Major plastic or reconstructive surgery patients at a high risk of developing thrombosis.

What does the study involve?

Following surgery patients will be randomly allocated to receive one of two, different antithrombotic drugs.

What are the possible benefits and risks of participating? Benefits: DVT risk reduction. No ultrasound study is charged to any participant. Risks: hematoma (localized bleeding outside of blood vessels), hyperkalemia (raised potassium in blood).

Where is the study run from?

American British Cowdray Santa Fe Medical Center, Mexico

When is the study starting and how long is it expected to run for? April 2016 to April 2018 Who is funding the study? Investigator initiated and funded

Who is the main contact? Dr Revilla-Peñaloza frevp3@gmail.com

Contact information

Type(s) Scientific

Contact name Dr Francisco Revilla-Peñaloza

ORCID ID http://orcid.org/0000-0003-1035-8957

Contact details

Anesthesiology Service, American British Cowdray Santa Fe Medical Center No. 154 Carlos Graef Fernandez Av. Santa Fe, Del. Cuajimalpa Mexico City Mexico 053333 +52 55 1103-1600 ext. 1701 ptrapaga@abchospital.com

Type(s)

Scientific

Contact name Dr Juan A. Molina Guarneros

ORCID ID http://orcid.org/0000-0002-1946-0408

Contact details

Faculty of Medicine Department of Pharmacology National Autonomous University of Mexico Av. Universidad 3000, Colonia Ciudad Universitaria, Alcaldía Coyoacán Mexico City Mexico 04510 +525556232164 jamg@unam.mx

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers ABC-15-17

Study information

Scientific Title

Randomised trial of deep vein thrombosis chemoprophylaxis with bemiparin and enoxaparin in patients with moderate to high thrombogenic risk undergoing plastic and reconstructive surgery procedures

Acronym

RATDEVETROBEMENOXA

Study objectives

Compared to enoxaparin, perioperative administration of bemiparin reduces deep vein thrombosis risk without significantly increasing bleeding hazards in plastic and reconstructive surgery patients with moderate to high thrombogenic risk

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 08/10/2015, Institutional Research and Research Ethics Committees The American British Cowdray Medical Center (Sur 136, No.116 Colonia las Américas., Mexico City, 01120, Mexico; (52)5552308097; relacionespublicas_obs@abchospital.com), ref: ABC 15-17

Study design

Single centre single blind randomized parallel trial

Primary study design Interventional

Secondary study design Randomised parallel trial

Study setting(s) Hospital

Study type(s) Prevention

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Deep vein thrombosis (DVT) lower limbs

Interventions

Six hours after the end of the surgical procedure patients were assigned according to a sequential list (each new patient was alternatively assigned to either treatment group by Dr. Juan Molina (outside reader) regardless of their anthropometric characteristics or clinical condition) for single-blind subcutaneous administration of either enoxaparin 40 IU (Group-E) or bemiparin 3500 IU (Group-B) every 24 hours (q24h). Low Molecular Weight Heparin (LMWH) treatment was delivered during at least 10 days.

All patients were evaluated for DVT through Doppler ultrasound mapping of the lower limbs.

Intervention Type Drug

Phase Phase II

Drug/device/biological/vaccine name(s)

Bemiparin (Heporax) and enoxaparin (Clexane).

Primary outcome measure

Lower limb thrombogenesis: using USG Sonosite Doppler Micromax and multifrequency linear transducer from 4 to 12 MHz, to study the pelvic limbs in transversal and longitudinal sections, which yielded images in both gray scale and color, and applying Valsalva maneuvers and compression in all superficial and deep veins to looking for Thrombosis or reflux at key points. Ultrasound studies were carried out 24 hours before and 3-5 days after surgery.

Secondary outcome measures

Postoperative bleeding, measured using daily surgical drains. Timepoint: 4 days in mastoplasty cases; 15 days in abdominoplasty cases

Overall study start date

18/03/2015

Completion date 30/04/2018

Eligibility

Key inclusion criteria

- 1. Informed consent
- 2. Major plastic or reconstructive surgery patients
- 3. Moderate to high thrombogenic risk according to Caprini's scale
- 4. Classified I-III according to American Society of Anesthesiology criteria

Participant type(s)

Patient

Age group Adult

Sex Both

Target number of participants 80 patients

Total final enrolment 78

Key exclusion criteria

Active bleeding
Heparin-induced thrombocytopenia
Platelet count under 100,000
Severe renal insufficiency
Coagulopathy
Recent intracranial surgery
Epidural anesthesia or lumbar puncture over the last 24 hours

Date of first enrolment 01/05/2016

Date of final enrolment 30/04/2018

Locations

Countries of recruitment Mexico

Study participating centre American British Cowdray Santa Fe Medical Center No. 154 Carlos Graef Fernandez Av. Santa Fe Del. Cuajimalpa Mexico City Mexico 053333

Sponsor information

Organisation

Institutional Research and Research Ethics Committees The American British Cowdray Medical Center, Mexico City.

Sponsor details

Sur 136 No.116 Colonia las Américas. Mexico City Mexico 01120 (52)5552308097, (52)5552308000. Ext.8497 relacionespublicas_obs@abchospital.com

Sponsor type Hospital/treatment centre

Website http://www.abchospital.com

ROR https://ror.org/03e36d037

Funder(s)

Funder type Other

Funder Name Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Submission to either Clinical and Applied Thrombosis/Hemostasis Journal or Thrombosis and Hemostasis.

Intention to publish date

30/08/2019

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available as participants did not agree to make the data public.

IPD sharing plan summary Not expected to be made available

Study outputs					
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2020		Yes	Νο